Natco India settles patent dispute with Onyx Therapeutics for blood cancer drug Carfilzomib

Natco Carfilzomib dispute settled

Natco has partnered with Breckenridge Pharmaceutical, which will market the product in the US.

Indian Drug maker Natco Pharma on May 30th, 2019 said it has reached an out-of-court settlement in the US with Onyx Therapeutics over patent litigation related to the generic versions of 10mg, 30mg and 60mg of Kyprolis Injection made by Amgen Inc. in California and Kyprolis® is a registered trademark of Onyx Therapeutics, Inc.

The settlement allows Natco and its partner Breckenridge to launch the generic version of Kyprolis in 2027 or sooner depending on certain occurrences.  The exact date of the launch is held as “confidential”.

NATCO believes that its 10mg ANDA is sole first to file and could be eligible for 180-days marketing exclusivity for the 10mg strength under certain circumstances. Kyprolis, or it’s generic called carfilzomib, had sales of $586 million for the year ending December 2018 in the United States of America. The drug is used in the treatment of relapsing multiple myeloma — a type of blood cancer.

“The parties have reached a settlement agreement and the District Court case has been dismissed,” Natco said in a statement to stock exchanges. “The parties cannot make further comment as to the terms of the Settlement Agreement,” the statement added.

Natco is a prolific litigant, often locking horns with its bigger rivals to knock off the patent protection on their drugs. The company manages the high cost of litigation by partnering with local companies in the US, and offering them a profit share for distributing the product which Natco supplies.

News Source: NatcoPharma.in, Google, Internet.

Shares of Natco dropped 0.65 percent and were trading at Rs 520.10 on BSE at 2.52 pm, while the benchmark Sensex gained 0.74 percent to 39,793.25 points.

Related posts

Leave a Comment

32 + = 38